Proxi Biotech
PrivateLast Round
Convertible Debt
Sep 8, 2026
Total Funding Raised
$2.09M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Proxi Biotech operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Convertible Debt round in September 2026.
Proxi Biotech is a biotechnology company that develops toxoid-based active immunotherapies to prevent recurrent bacterial infections caused by drug-resistant pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Proxi Biotech Comparables
Compare Proxi Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Elaris FlexCo | 84% | |
| GlyProVac ApS | 83% | |
| Vaxdyn | 82% |
For institutional investors. Book with your work email.
Proxi Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 8, 2026 | ||||
| Accelerator | Feb 25, 2025 | ||||
| Grant | Jun 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Proxi Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EIT Health | Grant |
| BioInnovation Institute | Convertible Debt, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$1.51M raised from BioInnovation Institute
- Mar 2, 2026
Grew 150% QoQ from 2 to 5 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 8, 2026
Proxi Biotech ApS, a spin-out from Statens Serum Institut, is developing a vaccine-based immunotherapy whose lead candidate targets recurrent Clostridium difficile infections as an alternative to treatments such as faecal microbiota transplantation.
For institutional investors. Book with your work email.
Proxi Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Proxi Biotech's valuation, stock price, and market status.
Is Proxi Biotech a public or private company?
Proxi Biotech is a private company.
What is the current stock price of Proxi Biotech?
Proxi Biotech is a private company, so its shares have no public market price. Caplight tracks Proxi Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Proxi Biotech worth (valuation)?
Valuation information for Proxi Biotech is not publicly available.
Can I buy Proxi Biotech stock?
Proxi Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Proxi Biotech's last funding round?
Proxi Biotech's most recent funding round was Convertible Debt on September 8, 2026.
Who are the main investors in Proxi Biotech?
Key investors in Proxi Biotech include EIT Health, BioInnovation Institute.
Will Proxi Biotech IPO soon?
No public IPO plans have been announced for Proxi Biotech.
How can I track Proxi Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Proxi Biotech's shares on secondary markets.